New Enterprise Associates

Vori Health offers an integrated medical practice specializing in treating musculoskeletal conditions. Its nationwide, evidence-based approach addresses back, neck, and joint issues through a unique, virtual-first care model. Patients are connected to a collaborative team consisting of a board-certified physician, health coach navigator, and physical therapist for comprehensive care.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Launchpad Therapeutics is an antibody-focused precision oncology company.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Evernow offers comprehensive women's healthcare services focused on menopause. Their platform provides online access to specialized doctors, evidence-based information, treatments, and supportive communities, empowering women to manage hormonal changes and improve their overall health.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Vori Health offers an integrated medical practice specializing in treating musculoskeletal conditions. Its nationwide, evidence-based approach addresses back, neck, and joint issues through a unique, virtual-first care model. Patients are connected to a collaborative team consisting of a board-certified physician, health coach navigator, and physical therapist for comprehensive care.

Spiras Health operates a healthcare service that delivers specialized care to patients' homes for those managing complex chronic conditions. Their multidisciplinary clinical team offers services enhanced by telehealth, digital communications, and remote monitoring, aiming to improve patients' quality of life and reduce unnecessary hospitalizations.

AllyAlign Health, Inc. is a care management company that specializes in supporting patients with chronic and complex medical conditions. Founded in 2013 and headquartered in Glen Allen, Virginia, the company operates an advanced care management platform that facilitates real-time, collaborative care across various healthcare settings. This platform connects patients with care teams and integrates essential health information, care plans, and benefits details, empowering users to make informed care decisions. It offers mobile and web-based access, allowing patients and their families to view, share, create, and update information conveniently from home or from afar. The company's central database is HIPAA compliant and consolidates data from diverse sources, including electronic health records, lab tests, and clinical systems, ensuring comprehensive and meaningful clinical insights through semantic data modeling.

Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.

Vori Health offers an integrated medical practice specializing in treating musculoskeletal conditions. Its nationwide, evidence-based approach addresses back, neck, and joint issues through a unique, virtual-first care model. Patients are connected to a collaborative team consisting of a board-certified physician, health coach navigator, and physical therapist for comprehensive care.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Cardionomic is a medical device company developing a catheter-based neuromodulation therapy for acute decompensated heart failure. The device delivers targeted electrical stimulation to cardiac nerves via placement in the right pulmonary artery through the internal jugular vein and modulates autonomic signals to improve ventricular contractility without increasing heart rate. The therapy aims to increase cardiac output, renal blood flow, urine production, and pharmacological tolerance while reducing deleterious hormonal signaling associated with heart failure. It addresses the root cause of ADHF by non-systemically enhancing contractility to improve in-hospital outcomes. The company was founded in 2007 and is based in New Brighton, Minnesota.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

MORE Health, Inc. is a healthcare technology company that has developed a cloud-based physician collaboration platform to facilitate joint diagnosis and treatment planning between attending doctors and specialists. Founded in 2013 and based in Foster City, California, the platform integrates a clinical database containing medical histories, hospital records, lab results, and medical images, along with secure communication tools for real-time discussions. MORE Health offers a variety of services, including a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, it now serves U.S. companies as a supplemental health benefit, providing employees access to top-tier medical expertise during serious health issues. With strategic alliances with prominent medical institutions, MORE Health aims to become a virtual global hospital for serious illnesses, ensuring patients receive the highest quality of diagnosis and treatment when needed.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.

MORE Health, Inc. is a healthcare technology company that has developed a cloud-based physician collaboration platform to facilitate joint diagnosis and treatment planning between attending doctors and specialists. Founded in 2013 and based in Foster City, California, the platform integrates a clinical database containing medical histories, hospital records, lab results, and medical images, along with secure communication tools for real-time discussions. MORE Health offers a variety of services, including a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, it now serves U.S. companies as a supplemental health benefit, providing employees access to top-tier medical expertise during serious health issues. With strategic alliances with prominent medical institutions, MORE Health aims to become a virtual global hospital for serious illnesses, ensuring patients receive the highest quality of diagnosis and treatment when needed.

Radiology Partners is a healthcare service company that provides radiology services through a network of onsite centers across multiple states. It delivers diagnostic and interventional radiology to hospitals, health systems, radiology practices, and other facilities, with investments and support designed to help clients grow their practices while preserving autonomy. The company focuses on transforming radiology for radiologists, practices, patients, and families by offering comprehensive imaging services and collaborative partnerships that improve efficiency and care. Radiology Partners is headquartered in Manhattan Beach, California.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Radiology Partners is a healthcare service company that provides radiology services through a network of onsite centers across multiple states. It delivers diagnostic and interventional radiology to hospitals, health systems, radiology practices, and other facilities, with investments and support designed to help clients grow their practices while preserving autonomy. The company focuses on transforming radiology for radiologists, practices, patients, and families by offering comprehensive imaging services and collaborative partnerships that improve efficiency and care. Radiology Partners is headquartered in Manhattan Beach, California.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Cartiva, Inc. is a medical device company focused on developing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage damage. Founded in 2011 and headquartered in Alpharetta, Georgia, Cartiva markets the Cartiva Synthetic Cartilage Implant, which is designed to mimic natural cartilage and alleviate pain by restoring the joint structure in affected areas, including the first metatarsophalangeal joint, ankle, and knee. Additionally, Cartiva offers the ProxiFuse Hammertoe Correction System for the fixation of osteotomies and reconstruction of lesser toes. The company sells its products through various distributors in regions such as Brazil, Canada, and the United Kingdom. With a management team and board composed of experts in orthopedics, Cartiva aims to enhance patient outcomes through effective treatments for cartilage injuries and related discomfort. As of October 2018, Cartiva operates as a subsidiary of a larger medical group.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Cardionomic is a medical device company developing a catheter-based neuromodulation therapy for acute decompensated heart failure. The device delivers targeted electrical stimulation to cardiac nerves via placement in the right pulmonary artery through the internal jugular vein and modulates autonomic signals to improve ventricular contractility without increasing heart rate. The therapy aims to increase cardiac output, renal blood flow, urine production, and pharmacological tolerance while reducing deleterious hormonal signaling associated with heart failure. It addresses the root cause of ADHF by non-systemically enhancing contractility to improve in-hospital outcomes. The company was founded in 2007 and is based in New Brighton, Minnesota.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development.

Cartiva, Inc. is a medical device company focused on developing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage damage. Founded in 2011 and headquartered in Alpharetta, Georgia, Cartiva markets the Cartiva Synthetic Cartilage Implant, which is designed to mimic natural cartilage and alleviate pain by restoring the joint structure in affected areas, including the first metatarsophalangeal joint, ankle, and knee. Additionally, Cartiva offers the ProxiFuse Hammertoe Correction System for the fixation of osteotomies and reconstruction of lesser toes. The company sells its products through various distributors in regions such as Brazil, Canada, and the United Kingdom. With a management team and board composed of experts in orthopedics, Cartiva aims to enhance patient outcomes through effective treatments for cartilage injuries and related discomfort. As of October 2018, Cartiva operates as a subsidiary of a larger medical group.

MORE Health, Inc. is a healthcare technology company that has developed a cloud-based physician collaboration platform to facilitate joint diagnosis and treatment planning between attending doctors and specialists. Founded in 2013 and based in Foster City, California, the platform integrates a clinical database containing medical histories, hospital records, lab results, and medical images, along with secure communication tools for real-time discussions. MORE Health offers a variety of services, including a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, it now serves U.S. companies as a supplemental health benefit, providing employees access to top-tier medical expertise during serious health issues. With strategic alliances with prominent medical institutions, MORE Health aims to become a virtual global hospital for serious illnesses, ensuring patients receive the highest quality of diagnosis and treatment when needed.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

U.S. Renal Care operates a nationwide network of outpatient, home, and specialty dialysis centers delivering in-center and at-home hemodialysis and peritoneal dialysis services for end-stage renal disease. The company runs acute dialysis programs in partnership with local hospitals and supports families, caregivers, and physicians in ESRD care. Founded in 2000 and headquartered in Plano, Texas, it develops and operates dialysis centers through collaborations with local nephrologists, serving tens of thousands of patients across multiple states and select territories, including Guam and, according to some sources, Saudi Arabia.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Pinetree is a Beijing-based company that specializes in providing professional home care services for senior citizens in China. Founded in 2004, Pinetree offers a range of services, including home care, wellness, and insurance, tailored to meet the diverse needs of seniors at various stages of life and with different health conditions. The company's mission is to enhance the physical and mental well-being of elderly individuals, promoting their confidence and ability to live independently while also helping to reduce medical care expenses. Pinetree collaborates with commercial partners to deliver integrated and restorative care, effectively bridging the gap between hospitals, community health centers, and the homes of patients and their families.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Cartiva, Inc. is a medical device company focused on developing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage damage. Founded in 2011 and headquartered in Alpharetta, Georgia, Cartiva markets the Cartiva Synthetic Cartilage Implant, which is designed to mimic natural cartilage and alleviate pain by restoring the joint structure in affected areas, including the first metatarsophalangeal joint, ankle, and knee. Additionally, Cartiva offers the ProxiFuse Hammertoe Correction System for the fixation of osteotomies and reconstruction of lesser toes. The company sells its products through various distributors in regions such as Brazil, Canada, and the United Kingdom. With a management team and board composed of experts in orthopedics, Cartiva aims to enhance patient outcomes through effective treatments for cartilage injuries and related discomfort. As of October 2018, Cartiva operates as a subsidiary of a larger medical group.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Bravo Health, Inc. is a managed care organization that specializes in providing Medicare Advantage options, catering specifically to Medicare beneficiaries, including those who are dually eligible for Medicare and Medicaid. The company offers a range of plans, including special needs plans for individuals receiving institutional care or those with chronic health conditions, as well as private fee-for-service plans that allow members to choose their healthcare providers. Additionally, Bravo Health provides Part D prescription drug plans to cover medication needs. The company operates in multiple states, including Delaware, Maryland, Pennsylvania, Texas, and Washington, and has expanded its services to offer prescription drug coverage in 43 states. Founded in 1996 and headquartered in Baltimore, Maryland, Bravo Health was previously known as Elder Health, Inc.

Nova Specialty Hospitals (formerly Nova Specialty Surgery) is a fully equipped medical facility located conveniently in your neighborhood. It brings cutting edge medical technology and internationally trained physicians under one roof to give patients easy access to quality, affordable healthcare. Nova's medical services are based on the out-patient care model that enables quicker diagnosis and reduces patients' recovery time. This healthcare delivery system optimizes our staff's efficiency while reducing operational costs, thereby providing incomparable value and convenience to our patients.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

SCI Solutions provides healthcare business process software to a national network of over 550 hospitals, diagnostic imaging centers, physician groups, and post-acute organizations. The company's cloud-based platform enhances healthcare systems through patent-protected, workflow-enabled solutions that streamline patient care across various service areas. With a processing capacity of more than 1.5 billion transactions annually, SCI's Order Facilitator and Schedule Maximizer are recognized as leading referral management and network scheduling platforms in the industry. These offerings have been ranked among the Best in KLAS by KLAS Research. SCI Solutions aims to improve the healthcare system by increasing outpatient volumes, coordinating patient transitions, and enhancing revenue compliance while reducing network leakage. Their platform optimizes patient access, intake, and engagement processes, enabling healthcare enterprises to provide a more consumer-friendly experience. By utilizing advanced rules and workflow engines, SCI Solutions helps healthcare providers proactively manage scheduling and resources, ultimately fostering better physician loyalty, patient satisfaction, and revenue growth.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

DSI Renal is a prominent provider of dialysis services in the United States, catering to patients with chronic kidney failure. The company operates healthcare centers focused on delivering comprehensive dialysis care, patient support, and assistance for individuals traveling with dialysis needs. DSI Renal aims to enhance its presence through strategic acquisitions, the development of new clinics, and organic growth initiatives, ensuring that it meets the evolving needs of patients diagnosed with kidney disease.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Founded in 2011, Rock Health is a venture capital firm based in San Francisco. It specializes in investing in and supporting startups working at the intersection of healthcare and technology, with a focus on digital health.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Transcept Pharmaceuticals, Inc. is engaged in the development of proprietary products aimed at addressing therapeutic needs in neuroscience. The company utilizes a unique delivery system that enhances drug penetration and accelerates their onset of action. Transcept is focused on creating rapid-acting formulations of several established pharmaceuticals, seeking to improve patient outcomes in various neurological conditions. The company has attracted investment from notable firms, including Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates, supporting its ongoing research and development efforts.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

ReShape is a company that specializes in providing non-surgical weight-loss solutions and services. Founded in 1998 and based in the United States, ReShape aims to support individuals in achieving their weight-loss goals through innovative approaches. While initially associated with Electronic Design Automation software for the ASIC market, the company has pivoted to focus on health and wellness, offering a range of services designed to aid in weight management without surgical intervention.

Vantage Oncology, Inc. specializes in providing comprehensive oncology care services, focusing on radiation oncology, medical oncology, and cancer treatment. The company addresses the increasing demand for advanced radiation therapies among cancer patients, hospitals, and physicians. Vantage offers a range of services, including radiation therapy and neurosurgical interventions for various cancer types, such as breast, lung, and prostate cancers. Additionally, Vantage promotes joint venture ownership opportunities, allowing physicians and hospitals to maintain control over their practices while benefiting from the company's extensive network and expertise in radiation oncology. This model not only enhances the capabilities of individual practices but also strengthens the overall quality of cancer care provided to patients.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Novacept is a company founded in 1995 that specializes in the design, development, manufacturing, and marketing of innovative therapeutic devices aimed at enhancing women's healthcare. The company's flagship product, the NovaSure Impedance Controlled Endometrial Ablation System, represents a next-generation medical device specifically created to address excessive menstrual bleeding due to benign causes in pre-menopausal women who have completed childbearing. Through its focus on quality and cost-effectiveness, Novacept is committed to improving healthcare outcomes for women.

ReShape is a company that specializes in providing non-surgical weight-loss solutions and services. Founded in 1998 and based in the United States, ReShape aims to support individuals in achieving their weight-loss goals through innovative approaches. While initially associated with Electronic Design Automation software for the ASIC market, the company has pivoted to focus on health and wellness, offering a range of services designed to aid in weight management without surgical intervention.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

ReShape is a company that specializes in providing non-surgical weight-loss solutions and services. Founded in 1998 and based in the United States, ReShape aims to support individuals in achieving their weight-loss goals through innovative approaches. While initially associated with Electronic Design Automation software for the ASIC market, the company has pivoted to focus on health and wellness, offering a range of services designed to aid in weight management without surgical intervention.

PPONEXT is a PPO services company that provides healthcare management and network services. PPONEXT offers access to a network of medical care providers, hospitals, and ancillary facilities to group health, workers' compensation, and other insurance payers in the Midwest, Texas, California, Florida, New Jersey, and Pennsylvania.

SCI Solutions provides healthcare business process software to a national network of over 550 hospitals, diagnostic imaging centers, physician groups, and post-acute organizations. The company's cloud-based platform enhances healthcare systems through patent-protected, workflow-enabled solutions that streamline patient care across various service areas. With a processing capacity of more than 1.5 billion transactions annually, SCI's Order Facilitator and Schedule Maximizer are recognized as leading referral management and network scheduling platforms in the industry. These offerings have been ranked among the Best in KLAS by KLAS Research. SCI Solutions aims to improve the healthcare system by increasing outpatient volumes, coordinating patient transitions, and enhancing revenue compliance while reducing network leakage. Their platform optimizes patient access, intake, and engagement processes, enabling healthcare enterprises to provide a more consumer-friendly experience. By utilizing advanced rules and workflow engines, SCI Solutions helps healthcare providers proactively manage scheduling and resources, ultimately fostering better physician loyalty, patient satisfaction, and revenue growth.

WebMD is a prominent provider of health information and services aimed at both consumers and healthcare professionals. The company offers a wide range of resources, including online health-focused publications and decision-support applications, that empower users to manage their health actively. WebMD delivers objective healthcare and lifestyle information through various platforms, enabling individuals to access critical data about conditions such as HIV, diabetes, depression, and cancer. It also serves healthcare professionals by providing access to clinical reference sources, the latest treatment options, and opportunities for continuing medical education. Additionally, WebMD collaborates with employers and health plans to offer personalized health information and decision support tools for employees and plan members, fostering informed choices regarding benefits, providers, and treatment options.

Clarify is a provider and developer of customer relationship management (CRM) software. Clarify provides software and services to different industries like telecommunications, technology, financial services, healthcare, consumer products, travel, and entertainment industries.